🔴 Lipocine is trading 5% down with no identified catalyst

Lipocine is trading at $1.63, down 5.16%, with no specific explanation identified for the October 12 decline.

• No October 12 announcement or specific explanation appears in Lipocine’s investor-relations releases; the latest listed release is the October 7 TLANDO approval.
• That earlier approval does not establish a cause for the October 12 decline.
• Market context shows no broad-index move large enough to explain the drop and cites no company-specific or sector catalyst.